

PRESS RELEASE

08 December 2021 08:45:00 CET

Inauguration of Senzime's manufacturing facility in Uppsala, Sweden

News: Uppsala, on December 8, 2021. Senzime announces today that the company has produced the first TetraGraph system in its new manufacturing facility in Uppsala, Sweden. This is a major step in the company's global expansion strategy as it means increased control over costs, quality, and manufacturing pace.

TetraGraph and the majority of its accessories will be manufactured in the facility for delivery to the global market via the company's own sales force or distributors in Senzime's 29 markets. The next generation of products will also be manufactured in the facility, where the proximity between the research and development department and production will contribute to increased opportunities to quickly reach out with innovative products.

In-house production offers increased opportunities for control over suppliers, and in the long term the company expects higher profitability based on lower production costs. European ranking shows that Uppsala is one of Europe's most innovative regions and the large proportion of companies in Life Science facilitates the recruitment of experienced staff.

Pia Renaudin, CEO of Senzime, says: "We take control of our production from start to finish, which provides increased flexibility and speed in all decisions. I am extremely proud of our team that in a short time has completed this project which has resulted in us now having an ISO 13485 and MDR compliant production facility."

Senzime was founded in Uppsala in 1999 and the company's shares are traded on Nasdaq Stockholm main market (ticker SEZI).

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Sensime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Sensime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

Inauguration of Sensime's manufacturing facility in Uppsala, Sweden